İsmail CAN, Gülname Fındık GÜVENDİ, Necmetin KIRTAK, Hüseyin Serhat İNALÖZ, Ayhan ERALP, Serap Sergül İNALÖZ, Jale SELLİ

The Relationship Between the Prenatal Exposure to Terbinafine and Abnormal Skin Development in the Newborn Rats

Çalışmamızda, gebelikte terbinafin kullanım güvenliğinin araştırılması amaçlanmıştır. Bu çalışmada deri gelişiminde makroskobik organ anomaliler, antropometrik ölçekler ve anormallikler açısından yeni doğan sıçanlarda prenatal terbinafin maruziyetinin teratojenik etkilerini araştırmak amacıyla tasarlandı. Dişi Wistar-albino sıçanları (250-300 g), rastgele olarak kontrol grubu (n=6, gebelik sırasında fizyolojik su), A grubu (n=6, 21 gün boyunca 20 mg/kg/gün terbinafin tedavisi), B grubu (n=6, 51 gün boyunca 20 mg/kg/gün terbinafin tedavisi) ve C gruplarına (n=6, 21 gün boyunca 60 mg/kg/gün terbinafin tedavisi) ayrıldı. Doğumdan sonra, her bir deney grubundan beş fare yavrusu intrakardiyak 10% formalin uygulaması yoluyla sakrifiye edildi. Deri biyopsileri karın bölgesinden elde edildi ve ışık mikroskobik analizi için hazırlandı. Hiperkeratoz, epidermal atrofi, düzensiz epidermal hücreler tüm terbinafin dozlarında gösterildi. Kıl foliküllerinde hasar grup B ve Cde gözlendi. Sonuç olarak, gebelik sırasında terbinafine maruziyet yeni doğan sıçanlarda deri anormallikleri ve büyüme geriliğine neden olabilir ve etkileri uygulama süresi ve doza bağlı olarak değişir.

Yeni Doğan Sıçanlarda Prenatal Terbinafine Maruziyeti ile Anormal Deri Gelişimi Arasındaki İlişki

The aim of our study is to investigate the safety of terbinafine usage in pregnancy. This study was designed to investigate the teratogenic effects of prenatal terbinafine exposure in newborn rats in terms of macroscopic organ anomalies, anthropometric scales and abnormalities in skin development. Female Wistar-Albino rats (250 300 g) were randomly divided into a control group (physiological saline, during pregnancy; n=6), group A (terbinafine treatment, 20 mg/kg/day, for 21 days; n=6), group B (terbinafine treatment, 20 mg/kg/day, for 51 days; n=6) and group C (terbinafine treatment, 60 mg/kg/day, for 21 days; n=6). After birth, five rat pups from each experimental group were sacrificed by intracardiac infusion of 10% formalin. Skin biopsies were performed from the abdominal region and prepared for light microscopic analysis. Hyperkeratosis, epidermal atrophy and disordered epidermal cell lineage were demonstrated in all terbinafine doses with increase in severity at higher doses. Damage to hair follicles was observed in groups B and C. In conclusion, terbinafine exposure during pregnancy can cause abnormalities of the skin and growth retardation in newborn rats, and the effects vary depending upon application time and dose.

PDF

___

1. van Gelder MM., van Rooij IA., Miller RK., Zielhuis GA., de Jong-van den Berg LT., Roeleveld N., 2010. Teratogenic mechanisms of medical drugs. Human Reproduction Update, 16, 378- 394.
2. DeVane L., Goetzl LM., Ramamoorthy S., 2011. Exposing fetal drug exposure. Clinical Pharmacology & Therapeutics, 89, 786-788.
3. Shehata HA., Nelson-Piercy C., 2000. Drugs to avoid in pregnancy. Current Obstetrics & Gynaecology, 10, 44-52.
4. Moore KL., Persaud TVN., Torchia MG., 2008. The developing human: clinically oriented embryology. 8th ed. 458-484, Saunders/Elsevier, Philadelphia.
5. Begg EJ., 2008. Prescribing in pregnancy and lactation. British Journal of Clinical Pharmacology, 65, 627-628.
6. Katic J., Fucic A., Gamulin M., 2010. Prenatal, early life, and childhood exposure to genotoxicants in the living environment. Archives of Industrial Hygiene and Toxicology, 61, 455-464.
7. Leyden J., 1998. Pharmacokinetics and pharmacology of terbinafine and itraconazole. Journal of the American Academy of Dermatology, 38, 42-47.
8. Suhonen R., Neuvonen PJ., 1997. The tolerability profile of terbinafine. Reviews in Contemporary Pharmacotherapy, 8, 373-386.
9. Gupta AK., Shear NH., 1997. Terbinafine: an update. Journal of the American Academy of Dermatology, 37, 979-988.
10. Maldonado RA., Molina J., Payares G., Urbina JA., 1993. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrobial Agents and Chemotherapy, 37, 1353-1359.
11. Contini C., Colombo D., Cultrera R., Prini E., Sechi T., Angelici E., Canipari R., 1996. Employment of terbinafine against pneumocystis carinii infection in rat models. British Journal of Dermatology, 46, 30-32.
12. Bahadir S., Inaloz HS., Alpay K., Agaoglu C., Cimsit G., Parlat P., Tak H., 2000. Continuous terbinafine or pulse itraconazole: a comparative study on onychomycosis. Journal of the European Academy of Dermatology and Venereology, 14, 422-423.
13. Fletcher H., Williams NP., Nicholson A., Rainford L., Phillip H., East-Innis A., 2000. Systemic phaeohyphomycosis in pregnancy and the puerperium. The West Indian Medical Journal, 49, 79-82.
14. King CT., Rogers PD., Cleary JD., Chapman SW., 1998. Antifungal therapy during pregnancy. Clinical Infectious Diseases, 27, 1151-1160.
15. Bar-Oz B., Moretti ME., Mareels G., Van Tittelboom T., Koren G., 1999. Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet, 13, 1700-1701.
16. Bar-Oz B., Moretti ME., Bishais R., Mareels G., Van Tittelboom T., Verspeelt J., Koren G., 2000. Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. American Journal of Obstetrics and Gynecology, 183, 617-620.
17. De Santis M., Di Gianantonio E., Cesari E., Ambrosini G., Straface G., Clementi M., 2009. First-trimester itraconazole exposure and pregnancy outcome a prospective cohort study of women contacting teratology information services in Italy. Drug Safety, 32, 239-244.
18. Czeizel AE., Metneki J., Kazy Z., Puho E., 2004. A population-based case-control study of oral griseofulvin treatment during pregnancy. Acta Obstetricia et Gynecologica Scandinavica, 83, 827-831.
19. Moudgal W., Sobel JD., 2003. Antifungal drugs in pregnancy: a review. Expert Opinion on Drug Safety, 2, 475-483.
20. Mesaik MA., Khan KM., Rahat S., Choudhary MI., Murad S., Abdullah NR., Ahmad A., Siddiqui RA., 2005. Immunomodulatory properties of synthetic imidazolone derivatives. Letters in Drug Design & Discovery, 2, 490-496.
21. Rubin PC., 1986. Prescribing in pregnancy; General principles. British Medical Journal, 293, 1415-1417.
22. Deveci E., Inaloz SS., Inaloz HS., 1998. Teratogenic effects of cadmium on rat skin. Acta Dermatologica-Kyoto, 93, 155-159.
23. Inaloz HS., Ketani MA., Inaloz SS., Yilmaz F., Ketani S., 2000a. The effects of sialoadenectomy and flutamide on skin development. Clinical and Experimental Obstetrics & Gynecology, 26, 231- 234.
24. Inaloz HS., Inaloz SS., Deveci E., Eralp A., 2000b. Teratogenic effects of nicotine on rat skin. Clinical and Experimental Obstetrics and Gynecology, 26, 241-243.
25. Inaloz HS., Sari I., Inaloz SS., Bayhan G., Unal B., Yayla M., Eralp A., Yuncu M., 2000c. The effects of unilateral uterine artery ligation on skin development. Clinical and Experimental Obstetrics & Gynecology, 26, 218-220.